• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>American journal of rhinology & allergy >The effect of montelukast sodium on serum arginase levels in patients with seasonal allergic rhinitis.
【24h】

The effect of montelukast sodium on serum arginase levels in patients with seasonal allergic rhinitis.

机译：孟鲁司特钠对季节性变应性鼻炎患者血清精氨酸酶水平的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Nitric oxide (NO) imbalance appears to be important in the pathogenesis of allergic rhinitis. NO is synthesized from l-arginine by NO synthase (NOS). Competing with NOS for l-arginine is arginase, which catalyzes the hydrolysis of arginine to urea and ornithine. Therefore, increased serum arginase activity could potentially limit NO production catalyzed by inducible NOS, thus contributing to allergic rhinitis. This study was designed to investigate the effect of the cysteinyl leukotriene type 1 receptor antagonist, montelukast sodium on serum arginase levels in patients with seasonal allergic rhinitis. METHODS: Twenty-five patients with seasonal allergic rhinitis (SAR; treatment group) and 16 nonasthmatic patients without allergic rhinitis (control group) were included in the study. Serum arginase levels and the mean total nasal symptoms scores were measured before and after oral montelukast sodium (10 mg) was administered daily for 4 weeks to the treatment group. RESULTS: Serum arginase levels and the mean total nasal symptoms scores were significantly lower in the treatment group after montelukast sodium administration compared with the baseline levels (p = 0.001). Serum arginase levels were significantly lower in the treatment group compared with the control group (p = 0.01). There was no statistically significant difference between the serum arginase levels of the treatment group before treatment and the control group (p = 0.05). There was a weak correlation between the mean total nasal symptoms scores and serum arginase levels in the treatment group before montelukast sodium administration (rs = 0.40; p = 0.05). CONCLUSION: Montelukast sodium may reduce serum arginase levels and total nasal symptoms scores of patients with SAR. Additional studies that compare the effectiveness of nasal corticosteroid and montelukast sodium on serum arginase levels should be conducted.
机译：背景：一氧化氮（NO）失衡似乎在过敏性鼻炎的发病机理中很重要。 NO通过NO合酶（NOS）从1-精氨酸合成。与NOS竞争的L-精氨酸是精氨酸酶，它催化精氨酸水解为尿素和鸟氨酸。因此，增加的血清精氨酸酶活性可能会限制诱导型NOS催化的NO产生，从而导致过敏性鼻炎。本研究旨在研究半胱氨酰白三烯1型受体拮抗剂孟鲁司特钠对季节性变应性鼻炎患者血清精氨酸酶水平的影响。方法：本研究纳入了25例季节性过敏性鼻炎患者（SAR;治疗组）和16例无过敏性鼻炎的非哮喘患者（对照组）。在治疗组每天口服孟鲁司特钠（10 mg）4周之前和之后，测量血清精氨酸酶水平和平均总鼻症状评分。结果：与基线水平相比，孟鲁司特钠给药后治疗组的血清精氨酸酶水平和平均总鼻部症状评分显着降低（p = 0.001）。与对照组相比，治疗组的血清精氨酸酶水平显着降低（p = 0.01）。治疗前治疗组和对照组的血清精氨酸酶水平无统计学差异（p = 0.05）。在服用孟鲁司特钠之前，治疗组的平均总鼻部症状评分与血清精氨酸酶水平之间的相关性较弱（rs = 0.40; p = 0.05）。结论：孟鲁司特钠可降低SAR患者的血清精氨酸酶水平和总鼻症状评分。应该进行其他比较鼻皮质激素和孟鲁司特钠对血清精氨酸酶水平有效性的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号